SAiL: proven efficacy in the elderly population
SAiL: efficacy data in patients ≤65 years and >65 years of age14
Reprinted with the kind permission of the author.
- Approximately 28% of patients evaluable for safety were >65 years of age.
- The median age for the elderly (>65 years) group was 70.
- Compared with patients aged ≤65 years, elderly patients (>65 years) treated with first-line Avastin-based therapy
- had a similar incidence of AEs of special interest
- had similar efficacy outcomes, with a remarkable median OS of 14.6 months in both populations.14
- Disclaimer: Avastin.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.avastin.comThe information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.